CPHI · XBRL financial data

China Pharma Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CPHI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	10,866	9,642	8,104	7,011	4,529	4,144
Cost of revenue	8,914	9,293	8,598	7,292	6,515	4,276
Gross profit	1,953	349	(494)	(281)	(1,986)	(132)
Research and development	378	319	186	240	284	281
General and administrative	1,823	1,651	1,893	1,466	1,785	2,451
Total operating expenses	4,531	3,210	3,055	2,471	2,603	3,107
Operating income (loss)	(2,578)	(2,861)	(3,549)	(2,752)	(4,589)	(3,239)
Interest income	6	3	11	7	—	—
Interest expense	294	542	435	334	27	27
Net income (loss)	(2,867)	(3,399)	(3,973)	(3,079)	(4,736)	(3,188)
Earnings per share, basic USD per share	—	(0.74)	(0.76)	(0.91)	(0.27)	(0.74)
Earnings per share, diluted USD per share	—	(0.74)	(0.76)	(0.91)	(0.27)	(0.74)
Weighted average shares, basic thousands of shares	—	4,613	5,257	3,384	17,464	4,291

Fiscal years (CPHI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	958	4,859	2,030	1,424	600	345
Accounts receivable	—	—	422	504	232	241
Inventory	3,705	3,340	2,948	3,733	2,266	1,621
Total current assets	5,322	9,093	5,965	5,997	3,270	2,346
Property and equipment, net	15,564	13,281	9,973	7,100	4,883	4,392
Right-of-use asset	50	128	39	117	38	182
Total assets	21,118	22,650	17,784	16,469	14,888	30,999
Accrued liabilities	177	298	405	299	247	351
Total current liabilities	11,404	10,513	12,739	6,821	5,017	7,400
Lease liability, non-current	—	44	—	40	—	112
Total liabilities	13,113	16,632	13,494	9,015	7,140	8,260
Accumulated deficit	(28,839)	(32,239)	(36,211)	(39,290)	(44,027)	(47,214)
Total stockholders' equity	8,005	6,018	4,290	7,455	7,748	22,740
Total liabilities and equity	21,118	22,650	17,784	16,469	14,888	30,999
Common shares outstanding (cover page) thousands of shares	45,580	47,340	8,458	14,817	32,619	40,522

Fiscal years (CPHI's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(2,867)	(3,399)	(3,973)	(3,079)	(4,736)	(3,188)
Depreciation and amortization	2,679	3,088	2,701	2,754	2,618	1,504
Net cash from operating activities	(42)	(250)	(410)	(700)	(466)	148
Purchases of property and equipment	867	438	402	12	38	59
Net cash from investing activities	(867)	(438)	(402)	(12)	(292)	(137)
Net cash from financing activities	624	4,598	(1,770)	73	27	(294)
Net change in cash	(227)	3,901	(2,829)	(606)	(797)	(282)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.